Findings

What do systematic reviews say?

63 questions · 66 findings · 10 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 12 · 18.2%GRADE not reported 3 · 4.5%Very low 15 · 22.7%Low 21 · 31.8%Moderate 14 · 21.2%High 1 · 1.5%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Prednisone vs placebo or supportive treatment · Children with any continuing kidney disease at 6 months
  Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
  RR 0.51 [0.24, 1.11]
  3 studies · 379 participants
  Moderate
Direct match · question page
- Prednisone vs placebo or supportive treatment · Persistent kidney disease at any time after treatment
  Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
  RR 0.74 [0.42, 1.32]
  5 studies · 746 participants
  Moderate
Direct match · question page
- Prednisone vs placebo or supportive treatment · Children with any continuing kidney disease at 12 months
  Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
  RR 1.06 [0.38, 2.91]
  3 studies · 455 participants
  Low
Direct match · question page
- Prednisone vs placebo or supportive treatment · Number developing severe kidney disease
  Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
  RR 1.58 [0.42, 6]
  2 studies · 418 participants
  Low
Direct match · question page
- Prednisone vs placebo or supportive treatment · Children with any continuing kidney disease at 3 months
  Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.46, 1.52]
  4 studies · 655 participants
  Moderate

Prednisone vs prednisone and plasma exchange (Gajdos 1983)

Score (MMS) day 30

1 finding from 1 review

Plasma exchange for generalised myasthenia gravis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Prednisone vs prednisone and plasma exchange (Gajdos 1983)

Score (MMS) month 12

1 finding from 1 review

Plasma exchange for generalised myasthenia gravis 2002 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Low

Prednisone vs placebo or supportive treatment

Persistent kidney disease at any time after treatment · patients with IgAV

Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.74 [0.42, 1.32]
5 studies · 746 participants
Moderate

Prednisone vs placebo or supportive treatment

Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).

2 findings from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.83 [0.46, 1.52]
4 studies · 655 participants
Moderate
Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.98 [0.7, 1.36]
3 studies · 487 participants
High

Prednisone vs placebo or supportive treatment

Children with any continuing kidney disease at 6 months · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.51 [0.24, 1.11]
3 studies · 379 participants
Moderate

Prednisone vs placebo or supportive treatment

Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).

2 findings from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.06 [0.38, 2.91]
3 studies · 455 participants
Low
Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.39 [0.75, 2.59]
2 studies · 287 participants
Moderate

Prednisone vs placebo or supportive treatment

Number developing severe kidney disease · patients with IgAV

Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.58 [0.42, 6]
2 studies · 418 participants
Low

Prednisone vs placebo

Activity limitations ‐ not measured · people with postpolio syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for postpolio syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prednisone vs placebo

Adverse events · people with postpolio syndrome

1 finding from 1 review

Treatment for postpolio syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
GRADE not reported

Prednisone plus azathioprine vs prednisone

Disease control · bullous pemphigoid

It is very uncertain whether prednisone plus azathioprine changes disease control (at 6 months) compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.93 [0.52, 1.66]
1 study · 67 participants
Very low

Prednisone plus azathioprine vs prednisone

Mortality (at 6 months) · bullous pemphigoid

It is very uncertain whether prednisone plus azathioprine changes mortality (at 6 months) compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 1.03 [0.35, 3.06]
1 study · 67 participants
Very low

Prednisone plus azathioprine vs prednisone

Quality of life ‐ not measured · bullous pemphigoid

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prednisone plus azathioprine vs prednisone

Adverse events · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Oral methotrexate and oral prednisone vs prednisone or placebo

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 2.31 [1.2, 4.45]
1 study · 70 participants
Low

Oral methotrexate and oral prednisone vs prednisone or placebo

Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 1.23 [0.75, 2.04]
1 study · 70 participants
Low

Oral methotrexate and oral prednisone vs prednisone or placebo

Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Oral methotrexate and oral prednisone vs prednisone or placebo

Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
GRADE not reported

Corticosteroids vs placebo

Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 147 participants
Moderate

Corticosteroids vs placebo

Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 111 participants
Moderate

Corticosteroids vs placebo

4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy

1 finding from 1 review

Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 152 participants
Moderate